Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yeo, Winnie ^a   Chen, Pei Jer ^b   Furuse, Junji ^c   Han, Kwang Hyub ^d   Hsu, Chiun ^b   Lim, Ho Yeong ^e   Moon, Hanlim ^f   Qin, Shukui ^g   Yeoh, Ee Min ^f   Ye, Sheng Long ^h  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c KYORIN UNIVERSITY   (Japan)

^d Yonsei University College of Medicine   (South Korea)

^e Samsung Medical Center   (South Korea)

^f GLAXOSMITHKLINE   (Singapore)

^g No 81 Hospital of PLA   (China)

^h ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; ANTIVIRUS AGENT; AVE 1642; BEVACIZUMAB; BORTEZOMIB; BRIVANIB; CAPECITABINE; CELECOXIB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INTERFERON; LAMIVUDINE; MITOMYCIN C; OXALIPLATIN; PAZOPANIB; PI 88; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; UFT; UNINDEXED DRUG; VANDETANIB;

ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; ASIAN; BLEEDING DISORDER; CANCER STAGING; CHINESE MEDICINE; CLINICAL STUDY; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DIARRHEA; DRUG MEGADOSE; FATIGUE; FEASIBILITY STUDY; FOOT DISEASE; HAND DISEASE; HEART LEFT VENTRICLE FAILURE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPONATREMIA; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LOW DRUG DOSE; MEDICAL EXPERT; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PORTAL HYPERTENSION; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; ASIA; CLINICAL TRIAL (TOPIC); LIVER TUMOR; METHODOLOGY; ONCOLOGY;

ASIA; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RESEARCH DESIGN;

EID: 78149265063     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-620     Document Type: Article

References (73)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150. 10.1200/JCO.2005.05.2308, 16682732.
3. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS, . for the Organizing Committee of the Japan-Korea Liver Symposium (JKLS) Epidemiology of hepatocellular carcinoma in Japan and Korea. Oncology 2008, 75(Suppl 1):13-16. 10.1159/000173419, 19092267, for the Organizing Committee of the Japan-Korea Liver Symposium (JKLS).
4. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347-354. 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2, 9455792.
5. Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis?. Aliment Pharmacol Ther 1998, 12:111-126. 10.1046/j.1365-2036.1998.00286.x, 9692685.
6. Llovet JM, Ricci S, Mazzaferro V, et al. for the SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514, for the SHARP Investigators Study Group.
7. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of Experts in HCC-Design Clinical Trials Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802, Panel of Experts in HCC-Design Clinical Trials.
8. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750. 10.1056/NEJM199903113401001, 10072408.
9. Everhart JE. Viral hepatitis. The burden of digestive diseases in the United States. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: US Government Printing Office, 2008: NIH Publication No. 09-6443, Everhart JE, Accessed November 13, 2009., http://www3.niddk.nih.gov/Burden_of_Digestive_Diseases/index.shtml#TOC
10. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007, 96:1127-1134. 10.1038/sj.bjc.6603649, 2360117, 17406349.
11. Yuen MF, Hou JL, Chutaputti A; Asia PW. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009, 24:346-353. 10.1111/j.1440-1746.2009.05784.x, 19220670.
12. Beasley R, Hwang L-Y, Lin C-C, et al. Hepatocellular carcinoma and hepatitis B virus: a prospecitve study of 22707 men in Taiwan. Lancet 1981, 2:1129-1133. 10.1016/S0140-6736(81)90585-7, 6118576.
13. Hsu C, Shen YC, Cheng CC, et al. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemp Clin Trials 2009,
14. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004, 8:794-805. 10.1016/j.gassur.2004.06.013, 15531232.
15. Chen C-H, Huanga G-T, Yanga P-M, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006, 42:2524-2529. 10.1016/j.ejca.2006.06.007, 16920352.
16. Cantarini MC, Trevisani F, Morselli-Labate AM, et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 2006, 101:91-98. 10.1111/j.1572-0241.2006.00364.x, 16405539.
17. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004, 41:427-435. 10.1016/j.jhep.2004.05.014, 15336446.
18. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004, 15:1661-1666. 10.1093/annonc/mdh430, 15520068.
19. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22:927-934. 10.1200/JCO.2004.05.161, 14990649.
20. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008, 28:28-38. 10.1111/j.1478-3231.2007.01618.x, 17976155.
21. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528. 2729097, 18378948.
22. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006, 43:233-240. 10.1002/hep.21024, 16440357.
23. Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2009,
24. Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22:1929-1935. 10.1111/j.1440-1746.2006.04707.x, 17914972.
25. Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009, 48:11-17. 10.2169/internalmedicine.48.1534, 19122351.
26. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009, 96:975-981. 10.1002/bjs.6731, 19672926.
27. Shen YC, Hsu C, Chen LT, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010,
28. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
29. Ikai I, Arii S, Ichida T, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005, 32:163-172. 10.1016/j.hepres.2005.04.005, 16024288.
30. Ferrante JM, Winston DG, Chen P-H, de la Torre AN. Family physicians' knowledge and screening of chronic hepatitis and liver cancer. Fam Med 2008, 40:345-351.
31. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999, 94:2224-222. 10.1111/j.1572-0241.1999.01297.x, 10445554.
32. Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007, 41:777-782. 10.1097/MCG.0b013e3180381560, 17700427.
33. Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002, 24:395-403. 10.1016/S1386-6346(02)00144-4, 12479938.
34. National Comprehensive Cancer Network NCCN Clinical practice guidelines in oncology: hepatobiliary cancers v.2.2009. Accessed September 25, 2009, National Comprehensive Cancer Network., http://www.nccn.org
35. Kee K-M, Wang J-H, Lee C-M, et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer 2007, 120:2650-2655. 10.1002/ijc.22616, 17304512.
36. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an american cohort. Hepatol 2005, 41:707-716.
37. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769. 10.1002/cncr.10384, 11920539.
38. Chinese Society of Liver Cancer The criteria of clinical diagnosis and staging of primary liver cancer. Chin J Hepatol 2001, 12:324. Chinese Society of Liver Cancer.
39. Yeo W, Liem TG, Chan SL, et al. Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- prospective validation of the Chinese University Prognostic Index Abstr. J Clin Oncol 2008, 26(May 20 suppl):4591.
40. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. The Oncologist 2007, 12:1425-1432. 10.1634/theoncologist.12-12-1425, 18165619.
41. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29:502-510. 10.1111/j.1478-3231.2008.01957.x, 2711257, 19141028.
42. Boursier J, Cesbron E, Tropet A-L, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol 2009, 43:580-585. 10.1097/MCG.0b013e3181889468, 19197195.
43. Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 2008, 23:1874-1878. 10.1111/j.1440-1746.2008.05527.x, 18752560.
44. Clinical practice guidelines for hepatocellular carcinoma 2005 version 1.0. Japanese Society of Hepatology. Updated 2005, Accessed December 6, 2009., http://www.jsh.or.jp/english/08-Treatment_algorithm.pdf
45. Korean Liver Cancer Study Group and National Cancer Center Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009, 15:391-423. 10.3350/kjhep.2009.15.3.391, 19783891, Korean Liver Cancer Study Group and National Cancer Center.
46. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol 2005, 42:1208-123.
47. Sugimachi K, Maehara S, Tanaka S, Shimada M. Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2001, 8:410-416. 10.1007/s005340100002, 11702249.
48. Jeng KS, Yang FS, Chiang HJ, Ohta I. Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization. World J Surg 1992, 16:1188-1191. 10.1007/BF02067099, 1333684.
49. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
50. Poon D, Anderson BO, Chen L-T, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118. 10.1016/S1470-2045(09)70241-4, 19880065.
51. Lee HC. Systemic chemotherapy of hepatocellular carcinoma - Korean experience. Oncology 2008, 75:114-118. 10.1159/000173432, 19092280.
52. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008, 99:159-165.
53. Meza-Junco J, Chu QS, Christensen O, Rajagopalan P, Das S, Stefanyschyn R, Sawyer MB. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009, 65:1-4. 10.1007/s00280-009-1096-4, 19672597.
54. Cheng AL, Chen YC, Yeh KH, et al. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996, 77:872-877. 10.1002/(SICI)1097-0142(19960301)77:5<872::AID-CNCR10>3.0.CO;2-0, 8608477.
55. Cheng AL, Yeh KH, Fine RL, et al. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 1998, 45:1955-1960.
56. Lu YS, Hsu C, Li CC, et al. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepatogastroenterology 2004, 51:815-819.
57. Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). 2008, American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Abstr 128.
58. Yau T, Chan P, Cheung FY, et al. Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer Suppl 2009, 7:20.
59. Shen YC, Hsu CH, Hsu C, et al. A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol Abstr 2009, 27(suppl). Abstr 4589.
60. Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23). J Clin Oncol Abstr 2009, 27(suppl). Abstr 4591.
61. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). 2008, American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Abstr 267.
62. Zhu AX, Sahani DV, di Tomaso E, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. J Clin Oncol Abstr 2008, 26(May 20 suppl). Abstr 452.
63. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10:794-800. 10.1016/S1470-2045(09)70171-8, 19586800.
64. Rauol JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol Abstr 2009, 27(suppl). Abstr 4577.
65. Finn RS, Kang Y, Park J, Harris R, Donica M, Walters I. Phase II, open label study of brivanib alaninate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. 2009, American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Abstr 200.
66. Toh HC, Chen P, Knox JJ, et al. International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC). Eur J Cancer Suppl 2009, 7:366. Abstr PD-6517.
67. Hsu C, Yang TS, Huo TL, et al. Evaluation of vandetanib in patients with inoperable hepatocellular carcinoma (HCC): a randomized, double-blind, parallel group, multicentre, phase II study. Joint ECCO 15 - 34TH ESMO Multidisciplinary Congress 2009 Abstract No: PD-6518. Accessed November 2, 2009., http://ex2.excerptamedica.com/CIW-09ecco/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=hsu&topicselected=*&selection=ABSTRACT&qryStartRowDetail=7
68. Yau CC, Chen PJ, Curtis M, et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol Abstr 2009, 27(suppl). Abstr 3561.
69. Govindarajan R, Siegel ER, Makhoul I, et al. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC). 2009, American Society of Clinical Oncology Gastrointestianl Cancers Symposium, Abstr 264.
70. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27:843-850. 10.1200/JCO.2008.18.3301, 19139433.
71. Kaseb AO, Iwasaki MM, Javle M, et al. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol Abstr 2009, 27(suppl). Abstr 4522.
72. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009, 50:958-968. 10.1016/j.jhep.2008.12.023, 19303160.
73. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:42.